Comprehensive Analysis of Novel Immune Checkpoint Neuropilins

Xue-li Bai,Li-hong He,Xiao-zhen Zhang,Meng-yi Lao,Jian Xu,Han-shen Yang,Ting-bo Liang

DOI: https://doi.org/10.21203/rs.3.rs-1601245/v1

2022-01-01

Abstract:Abstract Background: The traditional immune checkpoint blockade therapy benefits some patients with cancer, but there is a lack of response in certain cancers such as pancreatic adenocarcinoma (PAAD), motivating the enthusiasm of developing novel immune checkpoints and effective therapeutic targets. Methods: NRPs expression was analyzed via bioinformatics data, immunohistochemistry, western blotting, and multiplexed immunohistochemistry. The relationship of NRPs to tumor immunological features and biological function in PAAD and pan-cancer were evaluated by a series of bioinformatics methods such as ssGSEA, TIDE, Gene Ontology and KEGG. In vitro human PAAD cell proliferation, invasion, and migration were examined using the CCK8, Transwell, and scratch wound healing assays, respectively. In vivo efficacy studies, using C57BL/6 mice and nude mice with PAAD cell-derived orthotopic tumors, employed antibodies against NRP1. Survival curves were constructed for the orthotopic model. Results: The expression of NRPs was generally higher in tumor tissues and that it was associated with a poor prognosis and pessimistic response to immune checkpoint blockade therapy. In nearly all cancers, the expression of NRPs was positively correlated with the infiltration of myeloid immune cells and the expression of most immune checkpoint genes. As regards tumor microenvironment of human PAAD samples, NRP1 and NRP2 were widely expressed in numerous cells types. Functional enrichment analysis, in vitro and in vivo experiments suggested that NRP1 exhibit potential pro-tumor effects via not only immune-related but also immune-independent interactions. Conclusions: NRPs, especially NRP1, are attractive biomarkers and therapeutic targets for various cancers, especially PAAD, providing a new opportunity for tumor immunotherapy.